- Home
- ELVN
as of 12-04-2025 9:50am EST
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $41.20 | AVG Volume (30 days): | 486.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.30 - $25.96 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 20.05% |
AI-Powered ELVN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Enliven Therapeutics Inc. (ELVN)
PRESIDENT AND CEO
Avg Cost/Share
$21.82
Shares
12,500
Total Value
$272,738.75
Owned After
890,392
SEC Form 4
CHIEF OPERATING OFFICER
Avg Cost/Share
$17.64
Shares
6,667
Total Value
$116,034.16
Owned After
269,974
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$22.08
Shares
12,500
Total Value
$276,025.00
Owned After
915,188
SEC Form 4
PRESIDENT AND CEO
Avg Cost/Share
$21.33
Shares
12,500
Total Value
$266,653.75
Owned After
890,392
SEC Form 4
CHIEF OPERATING OFFICER
Avg Cost/Share
$20.10
Shares
6,667
Total Value
$133,992.70
Owned After
269,974
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$20.40
Shares
3,250
Total Value
$66,291.23
Owned After
23,000
SEC Form 4
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$20.25
Shares
4,000
Total Value
$81,005.20
Owned After
915,188
SEC Form 4
PRESIDENT AND CEO
Avg Cost/Share
$20.06
Shares
3,700
Total Value
$74,227.55
Owned After
890,392
SEC Form 4
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$20.03
Shares
1,500
Total Value
$30,045.00
Owned After
915,188
SEC Form 4
PRESIDENT AND CEO
Avg Cost/Share
$20.03
Shares
2,800
Total Value
$56,084.00
Owned After
890,392
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Nov 17, 2025 | Sell | $21.82 | 12,500 | $272,738.75 | 890,392 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Nov 7, 2025 | Sell | $17.64 | 6,667 | $116,034.16 | 269,974 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Oct 20, 2025 | Sell | $22.08 | 12,500 | $276,025.00 | 915,188 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Oct 17, 2025 | Sell | $21.33 | 12,500 | $266,653.75 | 890,392 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Oct 7, 2025 | Sell | $20.10 | 6,667 | $133,992.70 | 269,974 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Sep 29, 2025 | Sell | $20.40 | 3,250 | $66,291.23 | 23,000 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Sep 26, 2025 | Sell | $20.25 | 4,000 | $81,005.20 | 915,188 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Sep 26, 2025 | Sell | $20.06 | 3,700 | $74,227.55 | 890,392 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Sep 23, 2025 | Sell | $20.03 | 1,500 | $30,045.00 | 915,188 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Sep 23, 2025 | Sell | $20.03 | 2,800 | $56,084.00 | 890,392 |
Compare ELVN vs Leading Stocks
See how ELVN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ELVN Enliven Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.